title: Volume reductions in frontopolar and left perisylvian cortices in methamphetamine induced psychosis.
abstract: Consumption of methamphetamine disturbs dopaminergic transmission and sometimes provokes schizophrenia-like-psychosis, named methamphetamine-associated psychosis (MAP). While previous studies have repeatedly reported regional volume reductions in the frontal and temporal areas as neuroanatomical substrates for psychotic symptoms, no study has examined whether such neuroanatomical substrates exist or not in patients with MAP. Magnetic resonance images obtained from twenty patients with MAP and 20 demographically-matched healthy controls (HC) were processed for voxel-based morphometry (VBM) using Diffeomorphic Anatomical Registration using Exponentiated Lie Algebra. An analysis of covariance model was adopted to identify volume differences between subjects with MAP and HC, treating intracranial volume as a confounding covariate. The VBM analyses showed significant gray matter volume reductions in the left perisylvian structures, such as the posterior inferior frontal gyrus and the anterior superior temporal gyrus, and the frontopolar cortices, including its dorsomedial, ventromedial, dorsolateral, and ventrolateral portions, and white matter volume reduction in the orbitofrontal area in the patients with MAP compared with the HC subjects. The smaller regional gray matter volume in the medial portion of the frontopolar cortex was significantly correlated with the severe positive symptoms in the individuals with MAP. The volume reductions in the left perisylvian structure suggest that patients with MAP have a similar pathophysiology to schizophrenia, whereas those in the frontopolar cortices and orbitofrontal area suggest an association with antisocial traits or vulnerability to substance dependence.
authors.affiliation: Department of Neuropsychiatry, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan.
authors.forename: Yuta
authors.initials: Y
authors.lastname: Aoki
authors.forename: Lina
authors.initials: L
authors.lastname: Orikabe
authors.forename: Yoichiro
authors.initials: Y
authors.lastname: Takayanagi
authors.forename: Noriaki
authors.initials: N
authors.lastname: Yahata
authors.forename: Yuriko
authors.initials: Y
authors.lastname: Mozue
authors.forename: Yasuhiko
authors.initials: Y
authors.lastname: Sudo
authors.forename: Tatsuji
authors.initials: T
authors.lastname: Ishii
authors.forename: Masanari
authors.initials: M
authors.lastname: Itokawa
authors.forename: Michio
authors.initials: M
authors.lastname: Suzuki
authors.forename: Masayoshi
authors.initials: M
authors.lastname: Kurachi
authors.forename: Yuji
authors.initials: Y
authors.lastname: Okazaki
authors.forename: Kiyoto
authors.initials: K
authors.lastname: Kasai
authors.forename: Hidenori
authors.initials: H
authors.lastname: Yamasue
mesh_terms: D000328:Adult; D016022:Case-Control Studies; D000697:Central Nervous System Stimulants / Q000633:toxicity; D005260:Female; D005625:Frontal Lobe / Q000473:pathology*; D007839:Functional Laterality; D006801:Humans; D007091:Image Processing, Computer-Assisted; D008279:Magnetic Resonance Imaging; D008297:Male; D008694:Methamphetamine / Q000633:toxicity; D011618:Psychotic Disorders / Q000209:etiology / Q000473:pathology*; D013702:Temporal Lobe / Q000473:pathology*; D055815:Young Adult
chemical_list: D000697:Central Nervous System Stimulants; D008694:Methamphetamine